We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PaxVax

News List

Themis eyes phase 3 study for chikungunya vaccine after passing midstage test pharmatimes
November 09, 2018
There aren't any vaccines or treatments for the painful viral infection chikungunya, but with phase 2 results announced this week, Themis hopes it's one step closer to changing that.
Emergent BioSolutions to acquire PaxVax for $270m pharmaceutical-technology
August 14, 2018
US-based life sciences company Emergent BioSolutions has signed an agreement to purchase specialty vaccines developer PaxVax for $270m under a cash-based consideration.
Emergent BioSolutions to acquire PaxVax and two travel vaccines in $270M deal fiercepharma
August 14, 2018
After getting smallpox vaccine ACAM2000 from Sanofi and an anthrax treatment called raxibacumab from GlaxoSmithKline, Emergent BioSolutions is buying again, this time an entire company: PaxVax.
PaxVax Announces the Initiation of Phase 2b Trial for its Chikungunya Vaccine americanpharmaceuticalreview
April 27, 2018
PaxVax announced the enrollment of the first patient in its Phase 2b dose-finding trial of the chikungunya virus-like particle (VLP) vaccine